Exclusive Summary

• - Core patents expired; originator is Ferring (Pabal/Duratocin), and the standard injection is broadly open to generics in most markets.
• - PPH is the leading cause of maternal death: ~140 million births/year, ~14 million PPH cases, and ~30 million C-sections drive steady prophylactic demand.
• - WHO recommends uterotonics routinely; heat‑stable carbetocin is on the EML as an alternative where oxytocin quality/cold chain is unreliable.
• - Competition is originator plus multiple generics; heat‑stable suppliers remain few, enabling differentiation and first‑to‑market opportunities in several countries.
• - Compliance and cost are key: with international GMP/CTD experience, entry is faster, and generics typically price 30–70% below originator while saving cold‑chain and add‑on uterotonic costs.

Asset Materials

Contact Us for Full Materials